Vertex Pharmaceuticals Incorporated (VRTX) |
|
301.83 10.52 (3.61%)
|
07-07 15:04 |
|
Open: |
292.3 |
Pre. Close: |
291.31 |
|
High:
|
306.08 |
Low:
|
291.59 |
|
Volume:
|
1,060,599 |
Market Cap:
|
78,258M |
|
|
|
|
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
295.384 - 296.577 |
296.577 - 297.714 |
|
Low:
|
286.647 - 287.977 |
287.977 - 289.245 |
|
Close:
|
289.204 - 291.267 |
291.267 - 293.233 |
|
Technical analysis |
as of: 2020-07-07 2:40:08 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 357.50  One year: 417.56 |
| Support: |
Support1: 278.39 Support2: 261.28 |
| Resistance: |
Resistance1: 306.08 Resistance2: 357.50 |
| Pivot: |
288.89 |
| Moving Average: |
MA(5): 292.06 MA(20): 283.93
MA(100): 257.30 MA(250): 221.96 |
| MACD: |
MACD(12,26): 5.29 Signal(9): 4.49 |
| Stochastic oscillator: |
%K(14,3): 81.37 %D(3): 76.09 |
| RSI: |
RSI(14): 63.44 |
| 52-week: |
High: 306.08 Low: 165.23 Change(%): 68.6 |
| Average Vol(K): |
3-Month: 196827 10-Days: 150887 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.VRTX has closed below upper band by 5.3%. Bollinger Bands are 25.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 07 Jul 2020
Is Vertex Pharmaceuticals Incorporated (VRTX) Stock a Good Buy? - InvestorsObserver
Thu, 02 Jul 2020
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Wed, 01 Jul 2020
Vertex Pharmaceuticals Incorporated (VRTX) Plans and Analysts Expectations - The News Heater
Mon, 29 Jun 2020
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Thu, 25 Jun 2020
Riding the Trend or Protecting Profits: Vertex Pharmaceuticals Incorporated (VRTX) - The News Heater
Fri, 19 Jun 2020
Vertex Pharmaceuticals Incorporated (VRTX) Rises 5.04% for June 19 - Equities.com
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: Nasdaq Global Select |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
259 |
| Shares Float (M) |
259 |
|
% Held by Insiders
|
0.14 |
|
% Held by Institutions
|
97.83 |
|
Shares Short (K)
|
4,210 |
|
Shares Short P. Month (K)
|
3,970 |
Stock Financials |
|
EPS
|
5.780 |
|
EPS Est This Year
|
1.630 |
|
EPS Est Next Year
|
2.890 |
|
Book Value (p.s.)
|
24.940 |
|
Profit Margin
|
31.35 |
|
Operating Margin
|
34.17 |
|
Return on Assets (ttm)
|
13.3 |
|
Return on Equity (ttm)
|
27.0 |
|
Qtrly Rev. Growth
|
76.5 |
|
Gross Profit (p.s.)
|
7.174 |
|
Sales Per Share
|
18.590 |
|
EBITDA (p.s.)
|
6.749 |
|
Qtrly Earnings Growth
|
124.40 |
|
Operating Cash Flow (M)
|
2,060 |
|
Levered Free Cash Flow (M)
|
1,330 |
Stock Valuations |
|
PE Ratio
|
52.13 |
|
PEG Ratio
|
0.60 |
|
Price to Book value
|
12.08 |
|
Price to Sales
|
16.21 |
|
Price to Cash Flow
|
37.93 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
